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Background—Eplerenone is known to reduce time to first hospitalization for heart failure or cardiovascular death in patients
with heart failure and mild symptoms. In chronic diseases such as heart failure, characterized by repeat hospitalizations,
analyzing all heart failure hospitalizations, not just the first, should give a more complete picture of treatment benefits.
Methods and Results—The Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF)
trial compared eplerenone with placebo in 2737 patients with mild heart failure, followed for a median 2.08 years
(interquartile range, 1.08–3.10 years). Data were collected on all hospitalizations, with a focus on those due to heart failure.
Heart failure hospitalization rates in the eplerenone and placebo groups were 10.70 and 16.99 per 100 patient-years,
respectively. Allowing for skewness in the frequency of hospitalizations by using the negative binomial generalized linear
model, the rate ratio (eplerenone versus placebo) was 0.53 (95% confidence interval, 0.42–0.66; P0.0001). A plot of
cumulative hospitalization rates over time revealed that most of the reduced risk on eplerenone occurred in the first year of
follow-up. Several baseline variables strongly predicted the risk of hospitalization. More complex statistical methods,
adjusting for mortality (as informative censoring), made a negligible difference in these findings.
Conclusions—Eplerenone markedly reduces the risk of heart failure hospitalizations in patients with heart failure and mild
symptoms to a greater extent than is captured by only studying the time to first hospitalization. Future clinical trials in
heart failure would gain from incorporating repeat hospitalizations into their primary evaluation of treatment effects.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00232180.
(Circulation. 2012;126:2317-2323.)
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The three major consequences of heart failure are symp-toms, hospital admission due to worsening heart failure,
and premature death.1,2 Because symptoms are subjective and
hard to quantify, and because drugs that improve symptoms
have also been shown to increase mortality, death and
hospital admission have become the most important end
points used in clinical trials of new treatments for heart
failure.3–5 Typically, these are used together in a composite
outcome, usually analyzed as time to first event. This ap-
proach, however, does not measure the true burden of
hospital admissions due to worsening heart failure either for
the individual or for healthcare systems, because patients may
experience multiple, recurrent, admissions during the course
of their illness.6,7 Not only are these hospital admissions very
distressing for patients and their caregivers, but they are also
the major driver of the enormous cost of heart failure to
healthcare systems.8,9 Furthermore, it is not known whether
treatments are as effective at reducing recurrent events as
initial ones. Consequently, these recurrent, nonfatal events
are important to quantify, although it is uncertain how this
should be done statistically.10–12 Earlier heart failure studies
tried to address this issue with the “days alive and out of
hospital” method.13,14 Any analysis must also account for the
competing risk of death, given that admission with worsening
heart failure accentuates the risk of death (and that dead
patients can no longer be admitted).15
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To address this problem further, we examined the frequency
of first and recurrent admissions and their time course and
predictors in the Eplerenone in Mild Patients Hospitalization and
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Survival Study in Heart Failure trial (EMPHASIS-HF).16,17 We
also analyzed the effect of eplerenone on repeat admissions by
using a statistical approach that accounts for death.15
Methods
Study Design and Patients
The design and primary results of the EMPHASIS-HF trial have
been published previously.16,17 In brief, EMPHASIS-HF tested the
hypothesis that eplerenone would reduce the risk of death and the
risk of hospitalization among patients with systolic heart failure and
mild symptoms. A total of 2737 patients with New York Heart
Association class II heart failure and an ejection fraction of no more
than 35% were randomly assigned to receive eplerenone (up to 50
mg daily) or placebo, in addition to recommended therapy. The
primary end point of the study was a composite of death from
cardiovascular causes or hospitalization for heart failure. This article
describes the analysis of the repeat hospitalizations, focusing on
heart failure hospitalizations. All hospital admissions for suspected
heart failure were adjudicated by a blinded end point committee. The
previously published results were on all patient follow-up to May 25,
2010.17 Because there was a subsequent median follow-up of 4.5
months on assigned double-blind treatment (pending a protocol
amendment permitting all patients to receive eplerenone), this
analysis uses these additional follow-up data.
Statistical Analyses
All analyses were conducted in accordance to the intention-to-treat
principle. The 2 treatment groups were balanced with respect to
baseline characteristics. Differences in these baseline characteristics,
by the number of hospitalizations, were analyzed with analysis of
variance for continuous variables and by the 2 test for categorical
variables. The probability values reported are 2-sided.
Bar plots for the distributions of the number of hospitalizations per
person were created, separately, for all-cause, cardiovascular and
heart failure hospitalizations.
Cumulative Incidence of Heart
Failure Hospitalizations
Cumulative incidence of heart failure hospitalizations were calcu-
lated for the 2 treatment groups. Analyses of heart failure hospital-
ization rates can be confounded by the competing risk of death, so to
assess the impact of death on hospitalization rates, estimates of the
cumulative number of heart failure hospitalizations were also calcu-
lated by using the Ghosh and Lin15 nonparametric analysis of the
hospitalization rates that allow for mortality as a competing risk.
Hospitalization Rates
The average number of hospital admissions per 100 patient-years of
follow-up was calculated for heart failure hospitalizations. The rate
per patient-year of follow-up was calculated by dividing the total
number of heart failure hospital admissions in each treatment group
by the total follow-up duration of all patients in that group. This
simple analysis of heart failure hospitalizations (including repeats) is
based on the Poisson distribution, which assumes that all patients
have the same underlying risk of being hospitalized for heart failure.
A more appropriate alternative approach that allows for the different
individual tendencies (frailties) for repeat heart failure hospitaliza-
tion recurrence uses the negative binomial distribution.
Modeling of Heart Failure Hospitalization Rates
The negative binomial regression model was used to obtain an
estimate of the effect of eplerenone on the rate of heart failure
hospitalizations.11 The Poisson distribution is also commonly used to
compare event rates in different groups, but does not account for the
highly skewed distribution in the frequency of hospitalizations.10
Alternatively, a survival-based technique is the Andersen-Gill exten-
sion of the Cox proportional hazards model.12 The Poisson and
Andersen-Gill regression models, however, both assume indepen-
dence of events within individuals, an assumption that is clearly
violated because recurrent hospitalizations within individuals will be
dependent.10 The negative binomial is considered an attractive
distribution to use, because it naturally accommodates the different
probabilities for events across members of the population. This
distribution assumes that each patient has recurrent hospitalizations
according to an individual-specific Poisson event rate, and that the
Poisson rates vary according to a gamma distribution.11 The gamma
distribution is mathematically convenient and is a highly flexible
distribution.18 The negative binomial allows estimation of average
rates of heart failure hospitalizations in the eplerenone and placebo
groups, and estimation of the ratio of rates of hospitalizations for
heart failure in the 2 groups, as well. In addition, the negative
binomial regression model is simple and straightforward to use and,
in contrast with the Andersen-Gill approach, does not require
complicated data files (only 1 entry per patient). Simulation studies
have also shown that the negative binomial produces results that are
similar to the Andersen-Gill approach.12
Rate ratios, 95% confidence intervals, and probability values were
calculated with the use of models adjusted for the following
prespecified baseline covariates: sex, age, estimated glomerular
filtration rate, ejection fraction, body mass index, hemoglobin value,
heart rate, systolic blood pressure, diabetes mellitus, and a history of
hypertension, myocardial infarction, atrial fibrillation, and a left
bundle-branch block or QRS duration 130 ms. Sensitivity analyses
were performed by means of unadjusted models.
Results
Incidence of Hospital Admissions
The crude frequencies for hospital admissions of different
types, without accounting for differential length of follow-up,
are presented in Table 1. Of the 2737 patients randomly
assigned, 458 (17%) died and 1013 (37%) had at least 1
hospital admission for any cause during follow-up (median
25 months). The number of patients admitted for a cardio-
vascular cause was 753 (28%) of whom 463 (17%) were
admitted for heart failure. There were 1985 hospital admis-
sions in total (ie, taking account of first and repeat episodes),
of which 1328 (67%) were cardiovascular; 793 (60%) of
those were due to heart failure. This means that 40% of all
hospital admissions were due to heart failure.
Including repeat episodes, there were 481 hospital admis-
sions for worsening heart failure in the placebo group in
comparison with 312 hospitalizations in the eplerenone
group. This gives 35.0 hospitalizations per 100 patients in the
placebo group in comparison with 22.9 hospitalizations per
100 patients in the eplerenone group, which is a difference of
12 hospitalizations per 100 patients.
There were 277 (20%) patients with at least 1 heart failure
hospitalization in the placebo group in comparison with 186
(14%) patients in the eplerenone group. This represents a
difference of 6 patients per 100, and a 32% relative risk
reduction (95% confidence interval [CI], 20%–43% reduc-
tion; P0.0001). Smaller reductions were observed in car-
diovascular hospitalizations (21% relative risk reduction
[95% CI, 11%–31%; P0.0001]) and all-cause hospitaliza-
tions (16% relative risk reduction [95% CI, 7%–23%;
P0.0007]), indicating that the effect of eplerenone on
admissions is predominantly confined to the admissions due
to heart failure. This is illustrated in Figure 1, which shows
bar plots for the distributions of the crude numbers of
hospitalizations by treatment group. The treatment differ-
ences in cardiovascular hospitalizations that are not heart
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failure, and hospitalizations that are not cardiovascular, are
both much less than those due to heart failure and do not
achieve statistical significance. So, although heart failure
hospitalizations were only 40% of all hospitalizations ob-
served, it was on these hospitalizations that the treatment
effect was concentrated. All subsequent analyses are confined
to heart failure hospitalization only.
Baseline Characteristics of Patients Hospitalized
for Heart Failure
Several baseline characteristics were significantly associated
with the risk of hospitalization (at least once) for heart failure
(Table 2). Hospitalized patients tended to be older, have a
higher heart rate, lower blood pressure, lower left ventricular
ejection fraction, longer QRS duration/left bundle-branch
block, lower body mass index, ischemic etiology, longer
duration of heart failure, lower hemoglobin, higher serum
creatinine levels, and lower estimated glomerular filtration
rate. Additionally, those hospitalized were more likely to
have a history of previous heart failure hospitalization,
myocardial infarction, coronary artery bypass surgery, atrial
fibrillation, and diabetes mellitus. There were no statistically
significant differences in these characteristics in patients who
were hospitalized for heart failure only once in comparison
with those who were hospitalized twice or more.
Cumulative Rate of Heart Failure Hospitalizations
Figure 2 shows the cumulative crude number of admissions
for heart failure per 100 patients in the 2 treatment groups,
with early and continuing separation of the event curves for
each treatment. By 1 year, the cumulative number of heart
failure hospitalizations per 100 hundred patients was 20.26 on
placebo in comparison with 9.20 on eplerenone, a treatment
difference of 11.06 hospitalizations per 100 patients. Beyond
1 year, this difference continued to increase, but at a slower
rate (14.84 at 2 years and 18.88 at 3 years). Figure 3 shows
the ratio of the cumulative numbers of heart failure hospital-
izations between the eplerenone and placebo groups. This
ratio remained 0.4 for the first year, and attenuated slightly
to 0.6 by 2 years, after which it then appeared to remain
constant.
Estimates of the cumulative number of heart failure hos-
pitalizations per 100 people by using the Gosh and Lin
approach that did allow for death tended to be slightly lower
than the estimate that ignored mortality, although it made a
negligible difference in the treatment comparison.15
Table 1. Number of Patients Hospitalized and Number of
Hospital Admissions in EMPHASIS-HF
Placebo Eplerenone % Reduction
No. of patients 1373 1364 . . .
Total follow-up years 2830.91 2916.07 . . .
No. of deaths 253 205 18.44
No. of CV deaths 215 178 16.66
All-cause hospitalization
Patients with 1 admission 551 462 15.60
Patients with 2 admissions 256 195 23.33
Total admissions 1123 862 22.74
Cardiovascular hospitalization
Patients with 1 admission 423 330 21.47
Patients with 2 admissions 174 112 35.21
Total admissions 773 555 27.73
Heart failure hospitalization
Patients with no. of hospitalizations
1 167 119 . . .
2 60 41 . . .
3 24 13 . . .
4 12 6 . . .
5 10 2 . . .
6 4 1 . . .
7 0 2 . . .
8 0 1 . . .
10 0 1 . . .
Patients with 1 admission 277 186 32.41
Patients with 2 admissions 110 67 38.69
Total admissions 481 312 34.71
CV indicates cardiovascular; EMPHASIS-HF, Eplerenone in Mild Patients
Hospitalization and Survival Study in Heart Failure.
Figure 1. Distributions per person of (1) the number of heart failure hospitalizations, (2) cardiovascular hospitalizations that were not for
heart failure, and (3) all hospitalizations that were not for cardiovascular disease.
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Heart Failure Hospitalization Rates
Rates of heart failure hospitalizations were defined in each
treatment group as the total number of heart failure hospital-
izations divided by the total number of years of follow-up. In
the placebo group, there were 481 heart failure hospitaliza-
tions over 2830.91 years of follow-up in comparison with 312
heart failure hospitalizations over 2916.07 years of follow-up
in the eplerenone group. Thus, heart failure hospitalizations
rates, per 100 person-years, were 16.99 in the placebo group
and 10.70 in the eplerenone group, a rate ratio of 0.63 (95%
CI 0.55– 0.73, P0.0001). For those who died during
follow-up (253 on placebo in comparison with 205 on
eplerenone), the heart failure hospitalization rates per 100
person-years were 60.57 in the placebo group in comparison
with 56.01 in the eplerenone group. So heart failure hospi-
talization rates were much higher before death and were
rather similar between the 2 treatment groups.
Treatment with eplerenone greatly reduced the rate of heart
failure hospitalization. The negative binomial regression model
gave a rate ratio for the eplerenone group, in comparison with
the placebo group, of 0.53 (95% CI, 0.42–0.66; P0.0001).
Table 3 shows further results from a multivariable negative
binomial regression model that relates treatment and pre-
specified baseline covariates to heart failure hospitalization
rates. The rate ratio of heart failure hospitalizations, adjusted
for prespecified covariates, for eplerenone versus placebo,
was 0.53 (95% CI, 0.43–0.66; P0.0001), practically iden-
tical to the unadjusted analysis.
Baseline covariates independently associated with a higher
risk of 1 heart failure hospitalizations were estimated
glomerular filtration rate 60 mL/min per 1.73 m2, lower
body mass index, lower hemoglobin level, higher heart rate,
and lower systolic blood pressure. In addition, heart failure
hospitalization rates were greater among patients with a
history of diabetes mellitus or previous myocardial infarction.
Left bundle-branch block or QRS duration 130 ms were
also independently predictive.
Separate analyses were conducted for the first hospitaliza-
tion only and for repeat hospitalizations (after the first). In the
placebo and eplerenone groups there were 277 and 186 first
heart failure hospitalizations, respectively, giving corre-
Table 2. Baseline Characteristics According to Heart Failure Hospital Admission Status
Baseline Characteristics
No. of Heart Failure Hospitalizations
P*
0
n2274
1
n286
2
n177
Age 68.37.6 69.97.8 70.67.6 0.001
Female, n (%) 516 (22.7) 60 (21.0) 34 (19.2) 0.287
Heart rate, beats/min 72.915.2 76.217.0 76.015.7 0.001
Systolic blood pressure, mm Hg 12516.9 12116.4 12016.8 0.001
Diastolic blood pressure, mm Hg 75.010.2 73.210.0 72.810.5 0.001
Left ventricular ejection fraction, % 26.14.7 25.54.8 25.64.6 0.018
QRS duration, ms 12046.0 12435.3 13044.7 0.003
Body mass index, kg/m2 27.64.8 27.35.0 26.54.9 0.013
Ischemic heart disease, n (%) 1549 (68.1) 207 (72.4) 130 (73.4) 0.054
Duration of heart failure, y 4.485.62 5.746.06 5.726.40 0.001
Hemoglobin, g/dL 13.91.5 13.41.7 13.51.5 0.001
Serum creatinine, mg/dL 1.130.30 1.240.30 1.230.34 0.001
Estimated GFR, mL/min per 1.73 m2 72.221.8 62.917.6 65.023.4 0.001
Estimated GFR 60 mL/min per
1.73 m2, n (%)
694 (30.5) 135 (47.2) 83 (46.9) 0.001
Serum potassium, mmol/L 4.320.43 4.290.43 4.300.42 0.183
Medical history, n (%)
Hospitalization for heart failure 1127 (49.6) 190 (66.4) 123 (69.5) 0.001
Hypertension 1516 (66.7) 189 (66.1) 114 (64.4) 0.650
Angina pectoris 1001 (44.0) 116 (40.6) 72 (40.7) 0.194
Myocardial infarction 1121 (49.3) 158 (55.2) 102 (57.6) 0.008
PCI 488 (21.5) 66 (23.1) 42 (23.7) 0.409
CABG 401 (17.6) 65 (22.7) 50 (28.2) 0.001
Atrial fibrillation 678 (29.8) 107 (37.4) 59 (33.3) 0.012
Diabetes mellitus 665 (29.2) 122 (42.7) 72 (40.7) 0.001
Stroke 208 (9.15) 35 (12.2) 19 (10.7) 0.112
LBBB or QRS duration 130 ms
in nonpaced baseline ECG
873 (38.4) 137 (47.9) 101 (57.1) 0.001
Plus-minus values are means SD. GFR indicates glomerular filtration rate; PCI, percutaneous coronary intervention;
CABG, coronary artery bypass graft; and LBBB, left bundle-branch block.
*P value comparison between those patients not hospitalized and those hospitalized at least once.
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sponding rates of 9.7 and 6.4 per 100 patient-years and a
Poisson rate ratio of 0.65 (95% CI, 0.54–0.73; P0.0001).
Note that this analysis was based on the Poisson distribution
and did not need to allow for interdependence of hospitaliza-
tions within individuals, because the analysis took account of
only first admissions. A negative binomial regression model
was used to analyze repeat heart failure hospitalizations
(excluding the first). This gave a rate ratio for the eplerenone,
in comparison with placebo, of 0.52 (95% CI, 0.33–0.82;
P0.004).
Figure 4 shows the unadjusted and adjusted Cox propor-
tional hazards ratios for conventional time-to-first-event anal-
yses of the primary composite outcome of cardiovascular
death or heart failure hospitalization and heart failure hospi-
talization, and rate ratios for the Poisson and negative
binomial analyses of all, first, and repeat heart failure
hospitalizations described above, as well.
Discussion
These analyses of EMPHASIS-HF show that in systolic heart
failure with only mild symptoms, admission of patients to
hospital because of worsening heart failure is common and
repeat admission is frequent. Furthermore, eplerenone not
only reduces the risk of first admissions but decreases the
likelihood of second and subsequent admissions for heart
failure (and, in so doing, the overall number of patients
hospitalized and the total number of admissions for any
reason).
In the placebo group, 110 patients had a second or
subsequent hospital admission for heart failure in comparison
with 167 patients who experienced a single heart failure
hospitalization during follow-up. Crucially, the second and
subsequent events experienced by these 110 patients would
not count in a conventional time-to-first-event analysis. In
other words, 204 (42%) of the total of 481 admissions for
heart failure in the placebo group would have been unac-
counted for in conventional analyses. These repeat events
matter a great deal to patients (and their caregivers) and are an
important contributor to the economic burden of heart failure,
with most analyses showing that heart failure hospitalization
accounts for 70% of the total cost of this condition to
healthcare systems.8,9 In this respect, it is also noteworthy that
the patients studied had mild symptoms and were followed up
for a relatively short period (median 25 months); it would be
of interest to see similar analyses in more severely symptom-
Figure 3. Risk ratio (eplerenone versus placebo) of the cumula-
tive incidence of heart failure hospitalizations over time.
Table 3. Variables Associated With Heart Failure
Hospitalization Rates (Rate Ratio, 95% CI, and P Value) in a
Multivariate Regression Model
Rate
Ratio 95% CI P
Eplerenone vs placebo 0.53 (0.43–0.66) 0.0001
Female 0.79 (0.60–1.04) 0.0979
Age per 10 y 1.14 (0.98–1.34) 0.0941
Estimated GFR 60 mL/min per 1.73 m2 1.91 (1.50–2.43) 0.0001
Left ventricular ejection fraction 30% 0.83 (0.65–1.06) 0.1441
Body mass index per 5 kg/m2 0.83 (0.74–0.94) 0.0036
Hemoglobin per g/dL 0.90 (0.83–0.97) 0.0041
Heart rate per 10 beats/min 1.18 (1.10–1.26) 0.0001
Systolic blood pressure per 10 mm Hg 0.83 (0.77–0.89) 0.0001
Medical history
Diabetes mellitus 1.99 (1.58–2.51) 0.0001
Hypertension 0.92 (0.72–1.18) 0.5105
Myocardial infarction 1.30 (1.03–1.63) 0.0242
Atrial fibrillation 1.27 (1.00–1.62) 0.0522
LBBB or QRS duration 130 ms
in nonpaced ECG
1.69 (1.35–2.11) 0.0001
GFR indicates glomerular filtration rate; CI, confidence interval; and LBBB,
left bundle-branch block.
Figure 2. Estimated cumulative rate of heart failure hospitaliza-
tions per 100 patients, over time, by treatment group.
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atic patients and over longer periods of time. These recurrent
episodes are important in at least 2 other ways. First, it is
possible that a treatment might reduce the risk of a first
recurrence but be less effective in reducing subsequent
episodes, so that an overly optimistic assessment of the effect
of treatment might be deduced from a time to first analysis
(although the converse could also occur). Although this is a
recognized concern with anti-infective and anticancer thera-
pies, it is more hypothetical in cardiovascular disease, al-
though reactivation of the renin-angiotensin-aldosterone sys-
tem does occur during chronic angiotensin-converting
enzyme inhibitor treatment. We did not find any diminution
of effect of treatment with eplerenone. Second, we found that
a relatively small fraction of patients contributed dispropor-
tionately to the overall burden of admissions, and this
supports the findings of a similar analysis of the Multicenter
Automatic Defibrillator Implantation Trial with Cardiac Re-
synchronization Therapy7. If these individuals could be iden-
tified, they would be an appropriate target for more intensive
monitoring and treatment.
Although our data illustrate the importance of accounting
for repeat admissions, there is controversy concerning which
is the most appropriate approach to the statistical analysis of
recurrent events.10–12 A key issue is that recurrent events are
not independent (as illustrated by the clustering of recurrent
admissions in a small proportion of patients), rendering
standard statistical techniques that treat events as independent
observations invalid.19,20 Death is a confounding factor in
such analyses because, for example, in heart failure, patients
who are hospitalized are more likely to die than those who are
not (and the risk is increased more in those who experience
more admissions).13,19 A treatment difference in mortality
also results in an unequal duration of follow-up between
treatment groups. For example, in heart failure, it is known
that occurrence of a hospitalization for worsening heart
failure increases the risk of further admissions.7,20 On the
other hand, it is likely that admissions result in intensification
of therapy, clearly relevant in the present trial where a
nonstudy mineralocorticoid receptor antagonist may have
been started. We used 2 approaches to take account of these
concerns. One, the nonparametric method of Gosh and Lin
was used to take account of the competing risk of death.15 The
other, a negative binomial generalized linear model, was used
to account for the interdependence of events within an
individual.11
The Gosh and Lin analysis did not substantially alter the
estimate of the cumulative rate of heart failure admissions
(Figure 2). Because our patients had mild symptoms, the risk
of death was relatively low, so perhaps results of the 2
analyses might have been more different in a population with
a higher mortality rate.
It is clear that taking account of only first admissions
considerably underestimates the benefit of eplerenone on the
burden of heart failure. Considering only first admissions for
heart failure, in comparison with placebo, eplerenone treat-
ment prevented 6 admissions per 100 patients treated being
admitted at least once for worsening heart failure. However,
considering all hospitalizations for heart failure, eplerenone
prevented 12 hospital admissions per 100 patients treated.
Our analyses have some limitations. They were not prespeci-
fied. The statistical power for some comparisons was limited
as mentioned earlier. The differences between treatment
groups may have been attenuated by open-label use of
mineralocorticoid receptor antagonists in the placebo group
during follow-up, in particular, after a first hospitalization
(although this makes our analyses conservative).
In summary, our report illustrates the importance of recur-
rent events of patients with systolic heart failure, illustrates
approaches to their analysis, and demonstrates the potential
underestimation of the benefit of effective therapies if only
initial events are accounted for in a conventional time-to-
first-event end point. We suggest that analysis of recurrent
events should be routine in clinical trials in patients with heart
failure, as is the case in other disease states characterized by
frequent recurrent episodes.10
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CLINICAL PERSPECTIVE
The standard method of analysis of deaths and hospital admissions in clinical trials that only considers first events may no
longer be the most appropriate approach as cardiovascular diseases become more chronic conditions, increasingly
characterized by recurrent nonfatal episodes. We examined alternative approaches, taking account of repeat heart failure
hospitalizations (HFHs) in the The Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure trial
(EMPHASIS-HF). During the median 25 months extended double-blind follow-up, 186 of 1364 (14%) of eplerenone-
treated and 277 of 1373 (20%) of placebo-treated patients experienced at least 1 HFH, ie, a relative risk reduction of 32%
(95% confidence interval, 20–43); P0.0001, or 6 fewer HFHs per 100 patients treated. There were a total of 312 HFH
(10.7 per 100 person-years) in the eplerenone group in comparison with 481 (17.0) in the placebo group, giving a rate ratio
of 0.63 (95% confidence interval, 0.55–0.73); P0.0001, or 12 fewer HFHs per 100 patients treated. Of the 481 total HFHs
in the placebo group, 204 (42%) did not count in the time-to-first-event analysis. In the eplerenone and placebo groups,
there were 186 (6.4 per 100 person-years) and 277 (9.7) first HFH, respectively, giving a Poisson rate ratio of 0.65 (95%
confidence interval, 0.54–0.73); P0.0001. A negative binomial regression model used to analyze repeat HFH (excluding
the first), gave a rate ratio of 0.52 (95% confidence interval, 0.33–0.82); P0.004. Analyses of repeat events may give a
better assessment of the effect of treatment on the burden of chronic diseases such as heart failure.
Rogers et al EMPHASIS Repeat Hospitalizations 2323
 by guest on June 28, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
van Veldhuisen, Karl Swedberg, Harry Shi, John Vincent and Bertram Pitt
Jennifer K. Rogers, John J.V. McMurray, Stuart J. Pocock, Faiez Zannad, Henry Krum, Dirk J.
Repeat Hospitalizations
Eplerenone in Patients With Systolic Heart Failure and Mild Symptoms: Analysis of
Print ISSN: 0009-7322. Online ISSN: 1524-4539 
Copyright © 2012 American Heart Association, Inc. All rights reserved.
is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231Circulation 
doi: 10.1161/CIRCULATIONAHA.112.110536
2012;126:2317-2323; originally published online October 5, 2012;Circulation. 
 http://circ.ahajournals.org/content/126/19/2317
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
  
 http://circ.ahajournals.org//subscriptions/
is online at: Circulation  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Permissions and Rights Question and Answer this process is available in the
click Request Permissions in the middle column of the Web page under Services. Further information about
Office. Once the online version of the published article for which permission is being requested is located, 
 can be obtained via RightsLink, a service of the Copyright Clearance Center, not the EditorialCirculationin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 by guest on June 28, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
